Actas de congresos
Cardiovascular Pharmacogenetics [farmacogenética Cardiovascular]
Registro en:
Medicina. , v. 39, n. 4, p. 535 - 542, 2006.
766046
2-s2.0-34547895171
Autor
Sandrim V.C.
Rezende V.B.
Tanus-Santos J.E.
Institución
Resumen
The widely acknowledged variability in drug response is partiality due to differences in genetic background. Pharmacogenetics is a branch within the field of Clinical Pharmacology focused on the study of how genetic differences affect drug responses. Genetic variations (called polymorphisms) may change pharmacokinetic parameters (by altering enzymes involved in drug metabolism), and pharmacodynamic parameters (by altering receptor affinity by agonist and antagonist drugs). Presently, pharmacogenetics has been valued as a potentially useful tool in finding better therapeutics. This review is mostly concerned with cardiovascular pharmacogenetics. Clinical cases will be described and their possible pharmacogenetic implications will be briefly commented on. 39 4 535 542 Mooser, V., Waterworth, D.M., Isenhour, T., Middleton, L., Cardiovascular pharmacogenetics in the SNP era (2003) J Thromb Haemost, 1 (7), pp. 1398-1402 Hingorani, A.D., Liang, C.F., Fatibene, J., Lyon, A., Monteith, S., Parsons, A., A common variant of the endothelial nitric oxide synthase (Glu298Asp) is a major risk factor for coronary artery disease in the UK (1999) Circulation, 100 (14), pp. 1515-1520 Nakayama, M., Yasue, H., Yoshimura, M., Shimasaki, Y., Kugiyama, K., Ogawa, H., T-786-C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm (1999) Circulation, 99 (22), pp. 2864-2870 Ingelman-Sundberg, M., Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future (2004) Trends Pharmacol Sci, 25 (4), pp. 193-200 Schaefer, B.M., Caracciolo, V., Frishman, W.H., Charney, P., Gender, ethnicity and genetics in cardiovascular disease: Part 1: Basic principles (2003) Heart Dis, 5 (2), pp. 129-143 Sanderson, S., Emery, J., Higgins, J., CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet systematic review and meta-analysis (2005) Genet Med, 7 (2), pp. 97-104 Siffert, W., Cardiovascular pharmacogenetics: On the way toward individually tailored drug therapy (2003) Kidney Int, (SUPPL. 84), pp. S168-S171 Brookes, A.J., The essence of SNPs (1999) Gene, 234 (2), pp. 177-186 Anderson, J.L., Carlquist, J.F., Horne, B.D., Muhlestein, J.B., Cardiovascular pharmacogenomics: Current status, future prospects (2003) J Cardiovasc Pharmacol Ther, 8 (1), pp. 71-83 Endo, A., The discovery and development of HMG-CoA reductase inhibitors (1992) J Lipid Res, 33 (11), pp. 1569-1582 Brown, M.S., Goldstein, J.L., A receptor-mediated pathway for cholesterol homeostasis (1986) Science, 232 (4746), pp. 34-47 Gerdes, L.U., Gerdes, C., Kervinen, K., Savolainen, M., Klausen, I.C., Hansen, P.S., The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : A substudy of the Scandinavian simvastatin survival study (2000) Circulation, 101 (12), pp. 1366-1371 Bray, P.F., Cannon, C.P., Goldschmidt-Clermont, P., Moye, L.A., Pfeffer, M.A., Sacks, F.M., The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction (2001) Am J Cardiol, 88 (4), pp. 347-352 de Maat, M.P., Jukema, J.W., Ye, S., Zwinderman, A.H., Moghaddam, P.H., Beekman, M., Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis (1999) Am J Cardiol, 83 (6), pp. 852-856 Bolego, C., Baetta, R., Bellosta, S., Corsini, A., Paoletti, R., Safety considerations for statins (2002) Curr Opin Lipidol, 13 (6), pp. 637-644 Siest, G., Ferrari, L., Accaoui, M.J., Batt, A.M., Visvikis, S., Pharmacogenomics of drugs affecting the cardiovascular system (2003) Clin Chem Lab Med, 41 (4), pp. 590-599 Kajinami, K., Brousseau, M.E., Ordovas, J.M., Schaefer, E.J., CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia (2004) Am J Cardiol, 93 (1), pp. 104-107 Kurland, L., Lind, L., Melhus, H., Using genotyping to predict responses to anti-hypertensive treatment (2005) Trends Pharmacol Sci, 26 (9), pp. 443-447 Koopmans, R.P., Insel, P.A., Michel, M.C., Pharmacogenetics of hypertension treatment: A structured review (2003) Pharmacogenetics, 13 (12), pp. 705-713 Bianchi, G., Ferrari, P., Staessen, J.A., Adducin polymorphism: Detection and impact on hypertension and related disorders (2005) Hypertension, 45 (3), pp. 331-340 Mason, D.A., Moore, J.D., Green, S.A., Liggett, S.B., A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor (1999) J Biol Chem, 274 (18), pp. 12670-12674 Rigat, B., Hubert, C., Alhenc-Gelas, F., Cambien, F., Corvol, P., Soubrier, F., An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels (1990) J Clin Invest, 86 (4), pp. 1343-1346 Splawski, I., Timothy, K.W., Tateyama, M., Clancy, C.E., Malhotra, A., Beggs, A.H., Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia (2002) Science, 297 (5585), pp. 1333-1336 Tanus-Santos, J.E., Farmacogenetica em Cardiologia (2004) Rev SOCESP, 14 (3), pp. 530-538 Sandrim, V.C., Tanus-Santos, J.E., Farmacogenomica em hipertensão: Aspectos fisiológicos (2006) Hipertensão, 9 (1), pp. 4-8 Sandrim, V.C., Tanus-Santos, J.E., Farmacogenômica em hipertensão: Aspectos fisiopatológicos (2006) Hipertensão, 9 (1), pp. 9-14